Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

NCT06694454 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

60

Enrollment

NIH

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small Cell Lung
Non-Small Cell Lung Carcinoma
Non Small Cell Lung Cancer
Non Small Cell Lung Carcinoma

Interventions

DRUG: azacytidine
DRUG: carboplatin
DRUG: paclitaxel
DRUG: durvalumab
DRUG: cisplatin
DRUG: gemcitabine
DRUG: pemetrexed

Sponsor

National Cancer Institute (NCI)